
Bupropion
Bupropion is an established antidepressant and smoking-cessation aid. A network meta-analysis found all 21 antidepressants studied, including bupropion, better than placebo for adult depression. Three trials in 1,042 people with seasonal affective disorder found fewer winter depressions when bupropion XL was started in autumn. A Cochrane review rated the evidence high-certainty that bupropion increases long-term quit rates (risk ratio 1.60), though it is less effective than varenicline. St. John's wort is the moderate supplement interaction; alcohol is critical (seizure risk, including when heavy drinking stops suddenly) and nicotine replacement is moderate (blood pressure checks); seizure risk and MAO inhibitors are the main label cautions.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with major depressive disorder, adults with a history of autumn-winter seasonal depression (Wellbutrin XL, Aplenzin), and adults who want medicine to help quit smoking (bupropion SR), with a prescriber
Common dosing range
Set by your prescriber. Wellbutrin XL: 150 mg once daily in the morning, then usually 300 mg once daily. Wellbutrin SR: 150 mg once daily, then 150 mg twice daily at least 8 hours apart (maximum 400 mg a day). Smoking cessation (bupropion SR): 150 mg a day for 3 days, then 150 mg twice daily, not more than 300 mg a day, for 7 to 12 weeks
When to expect effects
Depression trials lasted 4 to 6 weeks; seasonal trials ran from autumn to spring; smoking trials measured quitting after at least 6 months
Watch out for
Boxed warning for suicidal thoughts and behaviors in children, teens and young adults. Can cause seizures: not for people with a seizure disorder, an eating disorder, or who are suddenly stopping alcohol or sedatives. Can raise blood pressure. Never combine with MAO inhibitors. Keep alcohol to a minimum or avoid it
What is it
Bupropion is a prescription antidepressant of the aminoketone class, sold as generic tablets in immediate-release, sustained-release (SR) and extended-release (XL) forms, and as Wellbutrin SR, Wellbutrin XL, Aplenzin (bupropion hydrobromide) and Forfivo XL (450 mg). The Wellbutrin XL and Aplenzin labels approve it for major depressive disorder and for preventing seasonal depressive episodes in seasonal affective disorder; Wellbutrin SR and Forfivo XL are approved for major depressive disorder. Bupropion is also approved as an aid to quitting smoking. The Wellbutrin labels say Wellbutrin itself is not approved for that use but contains the same active ingredient as Zyban, which is; Zyban has no current DailyMed listing, so this page uses a generic bupropion SR label that is approved for smoking cessation. Unlike most antidepressants it does not block serotonin reuptake. Its boxed warning covers suicidal thoughts and behaviors in young people. For supplements, St. John's wort is the moderate-severity interaction on this page and saffron a low-severity one.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
smoking cessation Strong Evidence | Moderate; about 60% more people quit than with placebo | Adults who smoke and want to quit, combined with counseling | Quitting measured after at least 6 months; treatment usually 7 to 12 weeks |
major depressive disorder in adults Good Evidence | Modest; response odds about 1.4 to 2.1 times placebo across antidepressants | Adults with major depressive disorder, without bipolar or psychotic features | Acute treatment trials lasting weeks |
prevention of seasonal affective disorder (autumn-winter depression) Good Evidence | Moderate; 44% relative reduction in seasonal depressive episodes | Adults with a history of autumn-winter seasonal major depression, starting treatment in autumn before symptoms | Over one autumn-to-spring season |
smoking cessation in people with and without psychiatric disorders Good Evidence | Moderate; odds of abstinence about twice placebo | Motivated adult smokers, including those with stable psychiatric conditions | Measured at weeks 9 to 12 |
smoking cessation
- Effect
- Moderate; about 60% more people quit than with placebo
- Best fit
- Adults who smoke and want to quit, combined with counseling
- Time
- Quitting measured after at least 6 months; treatment usually 7 to 12 weeks
major depressive disorder in adults
- Effect
- Modest; response odds about 1.4 to 2.1 times placebo across antidepressants
- Best fit
- Adults with major depressive disorder, without bipolar or psychotic features
- Time
- Acute treatment trials lasting weeks
prevention of seasonal affective disorder (autumn-winter depression)
- Effect
- Moderate; 44% relative reduction in seasonal depressive episodes
- Best fit
- Adults with a history of autumn-winter seasonal major depression, starting treatment in autumn before symptoms
- Time
- Over one autumn-to-spring season
smoking cessation in people with and without psychiatric disorders
- Effect
- Moderate; odds of abstinence about twice placebo
- Best fit
- Motivated adult smokers, including those with stable psychiatric conditions
- Time
- Measured at weeks 9 to 12
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
smoking cessation
Disease adjunctA 2023 Cochrane review of 124 studies found high-certainty evidence that bupropion increased long-term quit rates compared with placebo or no medicine (risk ratio 1.60, 95% CI 1.49 to 1.72; 50 studies, 18,577 people), with quitting measured after at least 6 months. Bupropion was less effective than varenicline (risk ratio 0.73) and combination nicotine replacement, and similar to single-form nicotine replacement. It caused more dropouts due to side effects than placebo (risk ratio 1.44, high certainty), and may increase serious adverse events (risk ratio 1.16, 95% CI 0.90 to 1.48, moderate certainty).
Bottom line: Bupropion reliably helps people quit smoking, though varenicline and combination nicotine replacement work better.
major depressive disorder in adults
Disease adjunctA 2018 network meta-analysis of 522 double-blind trials with 116,477 adults found that all 21 antidepressants studied, including bupropion, were more effective than placebo for acute treatment of major depression, with odds ratios from 1.37 to 2.13. The authors rated the certainty of evidence moderate to very low. Trials with many people with bipolar, psychotic or treatment-resistant depression were excluded. The Wellbutrin XL label also cites a placebo-controlled withdrawal trial in which people who kept taking bupropion SR after responding had fewer relapses over 44 weeks.
Bottom line: Bupropion works better than placebo for adult depression.
prevention of seasonal affective disorder (autumn-winter depression)
Disease adjunctThree randomized, placebo-controlled prevention trials enrolled 1,042 adults with seasonal affective disorder across the northern US and Canada while they were still well in autumn, and treated them with bupropion XL 150 to 300 mg a day or placebo until spring. Major depression came back in 19% versus 30%, 13% versus 21%, and 16% versus 31% in the three trials, a relative risk reduction of 44% overall. Almost 60% had never been treated for depression before, despite an average of 13 past seasonal episodes.
Bottom line: Starting bupropion XL in autumn reduced winter depressive episodes by 44% compared with placebo.
smoking cessation in people with and without psychiatric disorders
Disease adjunctThe EAGLES trial randomized 8,144 smokers, half with a psychiatric disorder, at 140 centers in 16 countries to bupropion 150 mg twice daily, varenicline, nicotine patch or placebo for 12 weeks. Bupropion did not significantly increase moderate or severe neuropsychiatric side effects compared with placebo or the patch: 2.2% versus 2.4% on placebo in people without psychiatric disorders, and 6.7% versus 4.9% in those with them (a difference that was not statistically significant). Bupropion raised continuous abstinence in weeks 9 to 12 compared with placebo (odds ratio 2.07) but less than varenicline. The trial was funded by the drug makers.
Bottom line: In a large trial, bupropion helped smokers quit without a significant rise in serious psychiatric side effects, though varenicline worked better.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; swallow the tablets whole, keep alcohol to a minimum or avoid it, and never take two bupropion products together.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Suicidal thoughts and behaviors (boxed warning). In pooled trials, antidepressants increased these in people under 25 (14 extra cases per 1,000 under 18 and 5 per 1,000 aged 18 to 24); everyone starting bupropion should be watched closely for worsening.
Seizures: dose-related. With bupropion SR up to 300 mg a day the incidence was about 0.1% (1 in 1,000); with immediate-release bupropion at 300 to 450 mg a day it was about 0.4%, and it rises almost tenfold between 450 and 600 mg a day. Other bupropion products, antipsychotics, antidepressants, theophylline, systemic corticosteroids, low blood sugar, heavy alcohol use and stimulant misuse add to the risk.
Neuropsychiatric events during smoking cessation: postmarketing reports include mood changes, psychosis, hallucinations, paranoia, aggression, hostility, agitation, anxiety, suicidal thinking and suicide; some people were still smoking. The label advises contacting a healthcare provider right away if such changes appear.
High blood pressure: bupropion can raise blood pressure, more so with MAO inhibitors or drugs that boost dopamine or norepinephrine. In a smoking trial, 6.1% on bupropion SR plus nicotine patch developed high blood pressure versus 2.5% on bupropion SR alone and 3.1% on placebo.
Other label warnings: activation of mania or hypomania (bupropion is not approved for bipolar depression), psychosis and confusion, angle-closure glaucoma, and allergic reactions from hives to anaphylaxis and Stevens-Johnson syndrome. Bupropion can cause false-positive urine screens for amphetamines.
Who should avoid it
- People with a seizure disorder, or a current or prior diagnosis of bulimia or anorexia nervosa (contraindicated)
- People undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiseizure drugs (contraindicated)
- People taking an MAO inhibitor for a psychiatric condition or within 14 days of stopping one, or being treated with linezolid or intravenous methylene blue (contraindicated), and people allergic to bupropion
- Children and teens: the label says safety and effectiveness in the pediatric population have not been established
Pregnancy & breastfeeding
Pregnancy: the Wellbutrin XL label says studies of women exposed to bupropion in the first trimester (675 exposures in an international registry and 1,213 in a US insurance database) have not shown a higher risk of birth defects overall. Findings on two specific heart defects (left ventricular outflow tract obstruction and ventricular septal defect) were inconsistent and do not allow conclusions. Women who stop antidepressants during pregnancy are more likely to relapse, so the risks of untreated depression also count. A national pregnancy registry for antidepressants collects outcomes. Breastfeeding: bupropion and its active metabolites pass into breast milk; in a study of 10 women, infant exposure averaged 2% of the mother's weight-adjusted dose. There are postmarketing reports of seizures in breastfed infants, with an unclear link to bupropion. The label says to weigh the benefits of breastfeeding against the mother's need for the medicine.
Interactions
Contraindicated because of an increased risk of hypertensive reactions (dangerous blood pressure rises). The label requires at least 14 days between stopping an MAOI and starting bupropion, and at least 14 days after stopping bupropion before starting an MAOI antidepressant.
Bupropion can cause seizures, and the label lists excessive alcohol use as a seizure risk factor and contraindicates bupropion in people who are abruptly stopping alcohol. It also reports rare cases of neuropsychiatric events or reduced alcohol tolerance in people who drank during treatment, and says alcohol should be minimized or avoided. If you usually drink a lot, do not stop drinking suddenly on your own; talk to your prescriber first.
The label says to use extreme caution, with low starting doses and gradual increases, because these drugs add to bupropion's seizure risk. Never take two bupropion products at once, such as one prescribed for depression and one for smoking.
Bupropion and its metabolites block CYP2D6. In a label study, bupropion raised desipramine exposure about 5-fold, an effect that lasted at least 7 days after the last bupropion dose. The label says doses of such drugs may need lowering, and that tamoxifen, which needs CYP2D6 to work, could in theory be less effective. Make sure each prescriber knows all your medicines.
In 18 healthy Chinese men given a single bupropion dose, 14 days of St. John's wort (325 mg three times daily) increased bupropion clearance from 108.3 to 130.0 liters per hour and lowered bupropion exposure, which could weaken its effect. A published case report describes facial dystonia (abnormal muscle movements) lasting about 5 months in a 58-year-old woman who had taken St. John's wort for years and started bupropion 150 mg a day to quit smoking; the authors could only propose a mechanism. Avoid combining them unless your prescriber advises it, and do not start or stop either one on your own.
This combination is often prescribed on purpose to help people quit smoking. In a trial in the label, new high blood pressure occurred in 6.1% of people on sustained-release bupropion plus a nicotine patch, compared with 2.5% on bupropion, 1.6% on the patch and 3.1% on placebo, mostly in people who already had high blood pressure. The label recommends blood pressure monitoring when the two are used together; make sure your prescriber knows about every nicotine product you use.
A 2023 systematic review lists blocking the reuptake of dopamine, norepinephrine and serotonin among saffron's proposed mechanisms, mostly from laboratory and animal work. Bupropion weakly blocks dopamine and norepinephrine reuptake, so a theoretical overlap exists, but the label says it does not inhibit serotonin reuptake, so a serotonin concern fits bupropion less well than other antidepressants. No trial has tested saffron with bupropion. In a placebo-controlled trial in 160 adults already taking an antidepressant, a standardized saffron extract (14 mg twice daily) for 8 weeks improved clinician-rated depression scores, but not self-rated scores, without increasing antidepressant side effects; its abstract does not name the antidepressants taken. The only trial that names them, a 4-week pilot in 40 adults, added crocin, a saffron compound, to the SSRIs fluoxetine, sertraline or citalopram. Discuss it with your prescriber before adding saffron.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ alcohol
criticalBupropion can cause seizures, and its label lists excessive alcohol use as a factor that raises seizure risk. The label contraindicates bupropion in people who are abruptly stopping alcohol, because sudden alcohol withdrawal also raises the chance of a seizure. It also reports rare postmarketing cases of neuropsychiatric events or reduced alcohol tolerance in people who drank during treatment, and says alcohol should be minimized or avoided. The evidence is FDA label warnings and postmarketing reports, not a controlled study of the pair.
+ st. john's wort
moderateSt. John's wort induces drug-metabolizing enzymes that can lower bupropion blood levels and weaken its effect. A human case report also links the pair to a prolonged movement (dystonic) reaction from overlapping effects on brain chemicals. The often-cited additive seizure risk rests mainly on animal extract studies and is not well supported in people.
+ nicotine
moderateBupropion and nicotine replacement are often used together on purpose to help people quit smoking, and the combination worked well in a large trial. In that trial, high blood pressure that appeared during treatment was more common with bupropion plus a nicotine patch (6.1%) than with bupropion alone (2.5%), the patch alone (1.6%) or placebo (3.1%), and most affected people already had high blood pressure. The bupropion label therefore recommends blood pressure monitoring for people who use the two together.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take St. John's wort with bupropion?⌄
This page rates the pair moderate and advises against combining them without your prescriber. In a study of healthy men, St. John's wort sped up the clearance of bupropion and lowered its levels, which could weaken it, and a case report describes abnormal facial movements with the combination. Talk to your prescriber before using it.
Can I take saffron supplements with bupropion?⌄
The concern is theoretical and fits bupropion less well, because the label says bupropion does not inhibit serotonin reuptake. No trial has tested saffron with bupropion. One trial added a saffron extract to unnamed antidepressants and found antidepressant side effects did not get worse; a small pilot added a saffron compound, crocin, to the SSRIs fluoxetine, sertraline or citalopram, and its abstract does not report side-effect results. This page rates the pair low severity. Ask your prescriber before starting it.
Can I drink alcohol while taking bupropion?⌄
The Wellbutrin XL label says alcohol use should be minimized or avoided, citing rare reports of neuropsychiatric events or reduced alcohol tolerance. Heavy drinking raises seizure risk, and suddenly stopping heavy drinking while on bupropion is contraindicated. Talk to your prescriber about your drinking before starting.
Is Wellbutrin the same as the bupropion used to quit smoking?⌄
Both contain bupropion. Wellbutrin SR and XL are labeled for depression, not for quitting smoking. Their labels say they contain the same active ingredient as Zyban, which is approved to help people quit; generic bupropion SR tablets labeled for smoking cessation are also available. The labels warn not to take two bupropion products together, because that raises the seizure risk.
Can bupropion cause seizures?⌄
Yes, and the risk rises with dose. With bupropion SR up to 300 mg a day, about 1 in 1,000 people had a seizure in studies. The label lists factors that raise the risk, including eating disorders, other medicines that lower the seizure threshold, heavy alcohol use and sudden stopping of alcohol or sedatives. Your prescriber increases the dose gradually to lower the risk.
References by claim
major depressive disorder in adults
Cipriani et al., 2018 · PMC (2018) link
prevention of seasonal affective disorder (autumn-winter depression)
Modell et al., 2005 · PubMed (2005) link
smoking cessation
Hajizadeh et al., 2023 · PMC (2023) link
smoking cessation in people with and without psychiatric disorders
Anthenelli et al., 2016 · PubMed (2016) link
Safety
Interaction: St. John's wort (Hypericum perforatum)
Interaction: Saffron (supplements)
Interaction: Nicotine replacement (patch, gum, lozenge, inhaler, nasal spray)
Jorenby et al., 1999 · PubMed (1999) link
Track Bupropion with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
